Raymond James & Associates Purchases 24,430 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Raymond James & Associates lifted its position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 35.9% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 92,441 shares of the company’s stock after acquiring an additional 24,430 shares during the quarter. Raymond James & Associates owned 0.19% of Nurix Therapeutics worth $923,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Exchange Traded Concepts LLC bought a new stake in shares of Nurix Therapeutics in the 2nd quarter worth about $123,000. Innovis Asset Management LLC purchased a new position in Nurix Therapeutics in the 1st quarter worth about $267,000. Mirae Asset Global Investments Co. Ltd. increased its stake in Nurix Therapeutics by 21.8% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 29,537 shares of the company’s stock worth $262,000 after buying an additional 5,279 shares during the period. Allspring Global Investments Holdings LLC increased its stake in Nurix Therapeutics by 328.7% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 5,264 shares of the company’s stock worth $53,000 after buying an additional 4,036 shares during the period. Finally, Arizona State Retirement System purchased a new position in Nurix Therapeutics in the 1st quarter worth about $91,000. Institutional investors own 90.36% of the company’s stock.

Nurix Therapeutics Stock Performance

NASDAQ NRIX opened at $6.46 on Friday. The company has a market capitalization of $313.31 million, a price-to-earnings ratio of -2.35 and a beta of 1.69. The company’s 50-day simple moving average is $7.28 and its two-hundred day simple moving average is $8.98. Nurix Therapeutics, Inc. has a one year low of $4.22 and a one year high of $15.09.

Nurix Therapeutics (NASDAQ:NRIX) last posted its earnings results on Thursday, October 12th. The company reported ($0.68) EPS for the quarter, beating analysts’ consensus estimates of ($0.84) by $0.16. Nurix Therapeutics had a negative net margin of 216.74% and a negative return on equity of 55.51%. The business had revenue of $18.47 million for the quarter, compared to the consensus estimate of $19.98 million. Equities analysts expect that Nurix Therapeutics, Inc. will post -2.36 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

NRIX has been the topic of several recent analyst reports. Needham & Company LLC reaffirmed a “buy” rating and issued a $31.00 price target on shares of Nurix Therapeutics in a research note on Friday, October 13th. Royal Bank of Canada reduced their price target on shares of Nurix Therapeutics from $29.00 to $24.00 and set an “outperform” rating on the stock in a research note on Thursday. Finally, HC Wainwright raised their price target on shares of Nurix Therapeutics from $33.00 to $35.00 and gave the stock a “buy” rating in a research note on Friday, September 8th. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $28.75.

Nurix Therapeutics Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.